The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).
 
Nick Van Dijk
No Relationships to Disclose
 
Alberto Gil Jimenez
No Relationships to Disclose
 
Karina Silina
No Relationships to Disclose
 
Kees Hendricksen
No Relationships to Disclose
 
Laura Smit
No Relationships to Disclose
 
Jeantine De Feijter
No Relationships to Disclose
 
Maurits L van Montfoort
No Relationships to Disclose
 
Annegien Broeks
No Relationships to Disclose
 
Yoni Lubeck
No Relationships to Disclose
 
Karolina Sikorska
No Relationships to Disclose
 
Thierry N. Boellaard
No Relationships to Disclose
 
Pia Kvistborg
Consulting or Advisory Role - Personalis (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Daniel J Vis
No Relationships to Disclose
 
Erik Hooijberg
No Relationships to Disclose
 
Ton Schumacher
Employment - Kite, a Gilead company
Leadership - Kite, a Gilead company
Stock and Other Ownership Interests - AIMM Therapeutics; Alimera Sciences; Kite, a Gilead company; Merus; Neogen; Neon Therapeutics; Scenic Biotech
Consulting or Advisory Role - AIMM Therapeutics; Allogene Therapeutics; Merus
Research Funding - Merck KGaA; MSD
 
Maries van den Broek
No Relationships to Disclose
 
Lodewyk FA Wessels
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Bas W.G. van Rhijn
No Relationships to Disclose
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche